Edwards Lifesciences (EW) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edwards Lifesciences (EW) has outperformed Tandem Diabetes Care (TNDM) over the past year, gaining 11.8% versus a gain of 9.1%. Over five years, EW leads with a -23.5% price change compared with -87.4% for TNDM. Edwards Lifesciences is the larger company by market cap ($49.44 billion vs $1.10 billion), about 44.9 times the size.
On valuation, Edwards Lifesciences trades at a lower forward P/E (25.4x vs 99.6x for Tandem Diabetes Care).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EW | TNDM |
|---|---|---|
| Share price | $85.78 | $15.84 |
| Market cap | $49.44B | $1.10B |
| 1-day change | -0.81% | -1.98% |
| YTD return | +0.62% | -27.93% |
| 1-year return | +11.81% | +9.09% |
| 5-year return | -23.52% | -87.36% |
| P/E ratio (TTM) | 51.06 | — |
| Forward P/E | 25.40 | 99.65 |
| EPS (TTM) | $1.68 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.07B | — |
| Revenue growth (YoY) | +11.55% | — |
| Net income (latest FY) | $1.07B | — |
| Gross margin | 78.01% | — |
| Operating margin | 20.84% | — |
| Net margin | 17.69% | — |
| 52-week high | $96.29 | $29.65 |
| 52-week low | $72.30 | $12.26 |
| Distance from 52-week high | -10.91% | -46.58% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +18.86% | +75.88% |
| Average volume | 3.82M | 1.98M |
| Shares outstanding | 576.40M | 69.58M |
| Employees | 16,000 | 2,500 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Edwards Lifesciences is about 44.9 times larger than Tandem Diabetes Care by market value ($49.44B vs $1.10B).
About Edwards Lifesciences
EW stock →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Healthcare · Medical Devices · 16,000 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Healthcare · Medical Devices · 2,500 employees
EW vs TNDM FAQ
Which is bigger, Edwards Lifesciences or Tandem Diabetes Care?
Edwards Lifesciences (EW) is larger, with a market capitalization of $49.44B compared with $1.10B for Tandem Diabetes Care (TNDM).
Which stock has performed better over the past year, EW or TNDM?
EW returned +11.81% over the past 12 months, compared with +9.09% for TNDM (price return, excluding dividends). Past performance does not predict future results.
Are Edwards Lifesciences and Tandem Diabetes Care in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.